CA2195856C - Substituted o6-benzylguanines and use thereof - Google Patents

Substituted o6-benzylguanines and use thereof Download PDF

Info

Publication number
CA2195856C
CA2195856C CA002195856A CA2195856A CA2195856C CA 2195856 C CA2195856 C CA 2195856C CA 002195856 A CA002195856 A CA 002195856A CA 2195856 A CA2195856 A CA 2195856A CA 2195856 C CA2195856 C CA 2195856C
Authority
CA
Canada
Prior art keywords
alkyl
amino
compound
group
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002195856A
Other languages
English (en)
French (fr)
Other versions
CA2195856A1 (en
Inventor
Robert C. Moschel
Anthony E. Pegg
M. Eileen Dolan
Mi-Young Chae
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Development Corp
Penn State Research Foundation
US Department of Health and Human Services
Original Assignee
Arch Development Corp
Penn State Research Foundation
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Development Corp, Penn State Research Foundation, US Department of Health and Human Services filed Critical Arch Development Corp
Priority to CA002632452A priority Critical patent/CA2632452A1/en
Publication of CA2195856A1 publication Critical patent/CA2195856A1/en
Application granted granted Critical
Publication of CA2195856C publication Critical patent/CA2195856C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002195856A 1994-08-01 1995-07-31 Substituted o6-benzylguanines and use thereof Expired - Fee Related CA2195856C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002632452A CA2632452A1 (en) 1994-08-01 1995-07-31 Substituted o6-benzylguanines and use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/283,953 US5525606A (en) 1994-08-01 1994-08-01 Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
US283,953 1994-08-01
PCT/US1995/009702 WO1996004281A1 (en) 1994-08-01 1995-07-31 Substituted o6-benzylguanines and 6(4)-benzyloxypyrimidines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002632452A Division CA2632452A1 (en) 1994-08-01 1995-07-31 Substituted o6-benzylguanines and use thereof

Publications (2)

Publication Number Publication Date
CA2195856A1 CA2195856A1 (en) 1996-02-15
CA2195856C true CA2195856C (en) 2008-09-30

Family

ID=23088285

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002195856A Expired - Fee Related CA2195856C (en) 1994-08-01 1995-07-31 Substituted o6-benzylguanines and use thereof
CA002632452A Abandoned CA2632452A1 (en) 1994-08-01 1995-07-31 Substituted o6-benzylguanines and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002632452A Abandoned CA2632452A1 (en) 1994-08-01 1995-07-31 Substituted o6-benzylguanines and use thereof

Country Status (10)

Country Link
US (8) US5525606A (enExample)
EP (3) EP1142893B1 (enExample)
JP (2) JP3981407B2 (enExample)
AT (2) ATE207490T1 (enExample)
CA (2) CA2195856C (enExample)
DE (2) DE69523462T2 (enExample)
DK (2) DK1142893T3 (enExample)
ES (2) ES2167451T3 (enExample)
PT (2) PT1142893E (enExample)
WO (1) WO1996004281A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043228A (en) * 1993-06-08 2000-03-28 Cancer Research Campaign Technology Limited O6 -substituted guanine derivatives, a process for their preparation and their use in treating tumor cells
US5929046A (en) * 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
US6794390B2 (en) * 1996-08-02 2004-09-21 Cv Therapeutics, Inc. Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
ES2253821T3 (es) * 1997-07-12 2006-06-01 Cancer Research Technology Limited Derivados de purina inhibidores de quinasa que depende de ciclina.
US6060458A (en) * 1998-02-13 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxyribonucleotides comprising O6 -benzylguanine and their use
GB9806739D0 (en) * 1998-03-28 1998-05-27 Univ Newcastle Ventures Ltd Cyclin dependent kinase inhibitors
US6677345B1 (en) * 1998-03-28 2004-01-13 Cancer Research Campaign Technology Limited Cyclin dependent kinase inhibitors
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
KR100368515B1 (ko) * 1999-02-03 2003-01-24 주식회사 엘지생명과학 싸이클린 의존 키나아제 저해제 및 그의 제조 방법
WO2008109417A1 (en) * 2007-03-02 2008-09-12 Case Western Reserve University Mgmt inhibitor combinations for the treatment of neoplastic disorders
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
WO2002036578A2 (en) * 2000-10-31 2002-05-10 Lynn Bonham Triazine derivatives as lpaat-b inhibitors and uses thereof
GB0101686D0 (en) * 2001-01-23 2001-03-07 Cancer Res Campaign Tech Cyclin dependent kinase inhibitors
AU2002313673B2 (en) * 2001-02-08 2006-09-07 Memory Pharmaceuticals Corporation Trifluoromethylpurines as phosphodiesterase 4 inhibitors
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
EP1440072A4 (en) * 2001-10-30 2005-02-02 Conforma Therapeutic Corp PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY
JP2005538134A (ja) * 2002-08-08 2005-12-15 メモリー・ファーマシューティカルズ・コーポレイション ホスホジエステラーゼ４阻害剤
US7335654B2 (en) * 2002-08-08 2008-02-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
GB0219746D0 (en) * 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
DE10307928A1 (de) * 2003-02-25 2004-09-16 Faustus Forschungs Cie. Translational Cancer Research Gmbh Verwendung von 1-(2-Chlorethyl)-1-nitroso-3-(2-hydroxyethyl)-urea zur Behandlung von Pankreaskarzinomen, Weichteilsarkomen, Hodentumoren, Lymphomen, Thymomen, Wilms Tumoren, Nierenkarzinomen, Melanomen, Lungentumoren, intracerebralen Metastasen, Tumoren im Kopf- und Halsbereich, und Mamma-Karzinomen
NZ546611A (en) * 2003-09-18 2010-02-26 Conforma Therapeutics Corp Novel heterocyclic compounds as HSP90-inhibitors
CA2552826A1 (en) * 2004-01-06 2005-07-28 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services 2-amino-o4-substituted pteridines and their use as inactivators of o6-alkylguanine-dna alkyltransferase
ES2329595T3 (es) * 2004-05-12 2009-11-27 Bayer Cropscience Ag Regulacion del crecimiento de las plantas.
CA2579660A1 (en) * 2004-09-08 2006-03-16 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services (The) Beta-glucuronidase cleavable prodrugs of o6-alkylguanine-dna alkyltransferase inactivators
US7825096B2 (en) * 2004-09-08 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs
CN100386115C (zh) * 2004-10-14 2008-05-07 孔庆忠 一种抗癌药物组合物
GB0502573D0 (en) * 2005-02-08 2005-03-16 Topotarget As Therapeutic compounds
AU2006230447A1 (en) 2005-03-30 2006-10-05 Conforma Therapeutics Corporation Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors
JP2008539198A (ja) * 2005-04-27 2008-11-13 コヴァリス・バイオサイエンシス・アーゲー Ｏ６−アルキルグアニン−ｄｎａアルキルトランスフェラーゼと反応するピリミジン
CN103259027A (zh) 2005-04-28 2013-08-21 普罗透斯数字保健公司 药物信息系统
WO2007024707A2 (en) 2005-08-22 2007-03-01 The Regents Of The University Of California Tlr agonists
EP1937258A2 (en) * 2005-09-23 2008-07-02 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
AU2007257423B8 (en) * 2006-05-31 2012-02-16 The Regents Of The University Of California Purine analogs
KR20090071598A (ko) 2006-09-18 2009-07-01 랩터 파마슈티컬 인코포레이티드 수용체 결합 단백질(ｒａｐ)-접합체 투여에 의한 간 질환의 치료
PL2125007T3 (pl) 2007-02-07 2014-07-31 Univ California Koniugaty syntetycznych agonistów TLR i ich zastosowania
WO2008137207A2 (en) * 2007-05-02 2008-11-13 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Inactivators of o6-alkylguanine-dna alkyltransferase
US8542442B2 (en) 2007-05-07 2013-09-24 Centre Suisse d'Electronique et de Microtechnique SA—Recherche et Developpement Isotropic zero-order diffractive filter
KR20100137449A (ko) * 2008-02-07 2010-12-30 더 리전트 오브 더 유니버시티 오브 캘리포니아 Ｔｌｒ７ 활성화제를 사용한 방광 질환의 치료
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
BRPI1008383A2 (pt) * 2009-02-11 2016-02-23 Univ California composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto
US20110305751A1 (en) 2009-02-20 2011-12-15 To-Bbb Holding B.V. Glutathione-based drug delivery system
AU2010245823B2 (en) 2009-05-06 2016-11-24 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
US20120270812A1 (en) * 2009-08-24 2012-10-25 Duke University Compositions, methods, and kits for determining an alkyl transferase
CN101850504B (zh) * 2010-05-06 2011-11-16 陕西理工学院 一种用两个步进电机控制主轴运动的振动制孔装置
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
GB201106814D0 (en) * 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
BR112013030442B1 (pt) * 2011-06-10 2021-11-09 Merck Patent Gmbh Compostos de pirimidina e piridina com atividade inibidora de btk, seus usos, composição, e kit
US20130236504A1 (en) * 2012-03-06 2013-09-12 Medical University Of South Carolina Delivery System for Enhancing Drug Efficacy
WO2014025749A2 (en) * 2012-08-06 2014-02-13 Sirga Advanced Biopharma, Inc. Small molecule inhibitors of viral protein interactions with human t-rna
ES2688194T3 (es) * 2014-09-11 2018-10-31 Bristol-Myers Squibb Company Inhibidores de mieloperoxidasa de triazolopirimidina y triazolopiridina de tioéter
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
IL64501A (en) * 1980-12-22 1985-07-31 Astra Laekemedel Ab 9-substituted 4-hydroxybutyl guanine derivatives,their preparation and antiviral use
US5260291A (en) 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US5731304A (en) * 1982-08-23 1998-03-24 Cancer Research Campaign Technology Potentiation of temozolomide in human tumour cells
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
EP0141927B1 (en) * 1983-08-18 1991-10-30 Beecham Group Plc Antiviral guanine derivatives
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
EP0184473A1 (en) * 1984-10-26 1986-06-11 Merck & Co. Inc. Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives
US4801710A (en) * 1984-10-26 1989-01-31 Merck & Co., Inc. Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives
US4751221A (en) * 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4965270A (en) * 1987-05-30 1990-10-23 Beecham Group P.L.C. Purine derivatives
US5723609A (en) * 1988-03-30 1998-03-03 E. R. Squibb & Sons, Inc. Bis (hydroxymethyl) cyclobutyl purines
US5091430A (en) * 1990-03-13 1992-02-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services O6 -substituted guanine compounds and methods for depleting O6 -alkylguanine-DNA alkyltransferase levels
US5691307A (en) * 1990-03-13 1997-11-25 The United States Of America As Represented By The Department Of Health And Human Services O6 -substituted guanine compositions and methods for depleting O6
US5352669A (en) * 1990-03-13 1994-10-04 The Of The United States Of America As Represented By The Department Of Health And Human Services O6 -benzylated guanine, guanosine and 2'-deoxyguanosine compounds possessing O6 -alkylguanine-DNA alkyltransferase depleting activity
WO1992000335A1 (en) * 1990-06-29 1992-01-09 Vinamul Limited Emulsion polymerisation
FR2676058B1 (fr) 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
DE4236237A1 (de) 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
DE4311651A1 (de) * 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
US6043228A (en) 1993-06-08 2000-03-28 Cancer Research Campaign Technology Limited O6 -substituted guanine derivatives, a process for their preparation and their use in treating tumor cells
WO1994029312A1 (en) 1993-06-08 1994-12-22 Cancer Research Campaign Technology Limited O6-substituted guanine derivatives, a process for their preparation and their use in treating tumour cells
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
ATE194920T1 (de) 1993-09-22 2000-08-15 Hoechst Ag Pro-prodrugs, ihre herstellung und anwendung
US5929046A (en) 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
SI0795334T1 (sl) 1996-03-12 2006-06-30 Sanofi Aventis Deutschland Predzdravila za zdravljenje tumorjev in vnetnih bolezni
US5965126A (en) 1996-03-25 1999-10-12 The Penn State Research Foundation use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents
WO1999025386A1 (en) 1997-11-13 1999-05-27 Case Western Reserve University delta-O6-METHYLGUANINE-DNA METHYLTRANSFERASE GENE TRANSFER FOR O6-BENZYLGUANINE AND (N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA) RESISTANCE

Also Published As

Publication number Publication date
DE69533900T2 (de) 2005-12-29
JP3981407B2 (ja) 2007-09-26
US20020013299A1 (en) 2002-01-31
ES2167451T3 (es) 2002-05-16
PT1142893E (pt) 2005-04-29
DK1142893T3 (da) 2005-03-29
EP1142893B1 (en) 2004-12-29
US6436945B2 (en) 2002-08-20
AU3207995A (en) 1996-03-04
JP2007077157A (ja) 2007-03-29
DE69523462T2 (de) 2002-07-11
JPH10508288A (ja) 1998-08-18
WO1996004281A1 (en) 1996-02-15
EP1518854A1 (en) 2005-03-30
US5753668A (en) 1998-05-19
US5916894A (en) 1999-06-29
US5525606A (en) 1996-06-11
ATE207490T1 (de) 2001-11-15
ATE286054T1 (de) 2005-01-15
US6172070B1 (en) 2001-01-09
CA2632452A1 (en) 1996-02-15
US5958932A (en) 1999-09-28
EP1142893A1 (en) 2001-10-10
EP0775142A1 (en) 1997-05-28
US6303604B1 (en) 2001-10-16
AU702711B2 (en) 1999-03-04
ES2233513T3 (es) 2005-06-16
DK0775142T3 (da) 2002-02-18
CA2195856A1 (en) 1996-02-15
PT775142E (pt) 2002-04-29
DE69523462D1 (de) 2001-11-29
EP0775142B1 (en) 2001-10-24
US6333331B1 (en) 2001-12-25
DE69533900D1 (de) 2005-02-03

Similar Documents

Publication Publication Date Title
CA2195856C (en) Substituted o6-benzylguanines and use thereof
CA1062257A (en) Purine compounds and salts thereof
EP2049491B1 (en) Heteroaryl compounds useful as inhibitors of e1 activating enzymes
US5929046A (en) Pyrimidine and purine derivatives and their use in treating tumour cells
EP0138656A1 (en) Cyclic pyrophosphates of purine and pyrimidine acyclonucleosides, their preparation and their application in anti-viral compositions
US7825096B2 (en) O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs
US4315920A (en) Adenosine deaminase inhibitors
US5646155A (en) Drugs to prevent recurrent herpes virus infections
US5002950A (en) 7-deazaguanines as immunomodulators
US4921858A (en) 7-deazaguanines as immunomodulators
EP0138683A2 (en) Purine derivatives, their application in anti-viral compositions
AU702711C (en) Substituted o6-benzylguanines and 6(4)-benzyloxypyrimidines
AU2005282562A1 (en) Beta-glucuronidase cleavable prodrugs of O6-alkylguanine-DNA alkyltransferase inactivators
US8188055B2 (en) Inactivators of O6-alkylguanine-DNA alkyltransferase
US5098905A (en) 7-deazaguanines as immunomodulators
US4996319A (en) -2-Amino-4,6-dichloro-5-(2-cyanomethyl-2-amino-5(cyanomethyl)-4,6-dichloro pyrimidine
CS203095B2 (cs) Způsob přípravy substituovaných purinů

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed